Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
FHCC
MCID: FBR086
MIFTS: 59

Fibrolamellar Carcinoma (FHCC)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Liver diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Fibrolamellar Carcinoma

About this section

MalaCards integrated aliases for Fibrolamellar Carcinoma:

Name: Fibrolamellar Carcinoma 12 52 15 17
Fibrolamellar Hepatocellular Carcinoma 12 52 58 43 71
Fibrolamellar Hepatocarcinoma 52 58
Fhcc 52 58
Eosinophilic Hepatocellular Carcinoma with Lamellar Fibrosis 52
Polygonal Cell Hepatocellular Carcinoma with Fibrous Stroma 52
Hepatocellular Carcinoma with Increased Stromal Fibrosis 52
Hepatocellular Carcinoma, Fibrolamellar 12
Eosinophilic Glassy Cell Hepatoma 52
Fibrolamellar Oncocytic Hepatoma 52
Oncocytic Hepatocellular Tumor 12
Fl-Hcc 52

Characteristics:

Orphanet epidemiological data:

58
fibrolamellar hepatocellular carcinoma
Inheritance: Not applicable; Prevalence: <1/1000000 (United States); Age of onset: Adolescent,Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Liver diseases Gastrointestinal diseases Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare hepatic diseases


External Ids:

Disease Ontology 12 DOID:5015
MeSH 43 C537258
NCIt 49 C4131
SNOMED-CT 67 15619004
ICD10 via Orphanet 33 C22.0
UMLS via Orphanet 72 C0334287
Orphanet 58 ORPHA401920
UMLS 71 C0334287
Sources

Summaries for Fibrolamellar Carcinoma

About this section
NIH Rare Diseases : 52 Fibrolamellar carcinoma (FLC) is a rare form of liver cancer which is generally diagnosed in adolescents and young adults (before age 40). Many people with early FLC have no signs or symptoms of the condition. When present, symptoms are often nonspecific (i.e. abdominal pain, weight loss, malaise ) and blamed on other, more common conditions. The exact underlying cause of FLC is poorly understood. Unlike other forms of liver cancer, FLC typically occurs in the absence of underlying liver inflammation or scarring; thus, specific risk factors for this condition remain unidentified. FLC is typically treated with surgical resection .

MalaCards based summary : Fibrolamellar Carcinoma, also known as fibrolamellar hepatocellular carcinoma, is related to mixed fibrolamellar hepatocellular carcinoma and intrahepatic cholangiocarcinoma, and has symptoms including fever, abdominal pain and icterus. An important gene associated with Fibrolamellar Carcinoma is PRKACA (Protein Kinase CAMP-Activated Catalytic Subunit Alpha), and among its related pathways/superpathways are Actin Nucleation by ARP-WASP Complex and PI3K-Akt signaling pathway. The drugs Vancomycin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include liver, lung and ovary, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A hepatocellular carcinoma characterized microscopically by laminated fibrous layers interspersed between the tumour cells. The polygonal, deeply eosinophilic tumor cells arise in non-cirrhotic livers.

Wikipedia : 74 Fibrolamellar hepatocellular carcinoma (FHCC) is a rare form of hepatocellular carcinoma (HCC) that... more...

Sources

Related Diseases for Fibrolamellar Carcinoma

About this section

Diseases related to Fibrolamellar Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 214)
# Related Disease Score Top Affiliating Genes
1 mixed fibrolamellar hepatocellular carcinoma 32.7 PRKACA GOLGA6L2 DNAJB1
2 intrahepatic cholangiocarcinoma 31.2 KRT7 FGFR2 AFP
3 cholangiocarcinoma 30.9 KRT8 KRT7 FGFR2 CCKBR AFP
4 pancreatoblastoma 30.8 SYP NTS AFP
5 pancreatic cancer 29.6 NTS MIR375 KRT8 KRT7 GAST FGFR2
6 ovary neuroendocrine neoplasm 10.7 SYP KRT7
7 endometrial transitional cell carcinoma 10.7 SYP KRT7
8 ovarian large-cell neuroendocrine carcinoma 10.7 SYP KRT7
9 mucinous adenofibroma 10.7 SYP KRT7
10 fgfr-related craniosynostosis syndromes 10.7 FGFR2 FGFR1
11 small cell carcinoma of the bladder 10.7 SYP KRT7
12 urinary bladder small cell neuroendocrine carcinoma 10.7 SYP KRT7
13 auditory system cancer 10.6 SYP KRT7
14 proliferating trichilemmal cyst 10.6 KRT8 KRT7
15 endolymphatic sac tumor 10.6 KRT8 KRT7
16 plagiocephaly 10.6 FGFR2 FGFR1
17 subareolar duct papillomatosis 10.6 KRT8 KRT7
18 nipple neoplasm 10.6 KRT8 KRT7
19 krukenberg carcinoma 10.6 SYP KRT7
20 vaginal tubulovillous adenoma 10.6 SYP KRT7
21 vaginal adenoma 10.6 SYP KRT7
22 middle ear adenoma 10.6 SYP KRT7
23 eccrine papillary adenocarcinoma 10.6 SYP KRT7
24 rosette-forming glioneuronal tumor 10.6 SYP FGFR1
25 hepatocellular carcinoma 10.6
26 jejunal neoplasm 10.6 SYP KRT7
27 vaginal benign neoplasm 10.6 SYP KRT7
28 sensory organ benign neoplasm 10.6 SYP KRT7
29 gastrointestinal neuroendocrine benign tumor 10.6 SYP GAST
30 mixed ductal-endocrine carcinoma 10.6 SYP GAST
31 appendix adenocarcinoma 10.6 SYP KRT7
32 syndromic craniosynostosis 10.6 FGFR2 FGFR1
33 mucinous ovarian cystadenoma 10.6 KRT7 GAST
34 primary hepatic neuroendocrine carcinoma 10.6 VIM SYP
35 osteoglophonic dysplasia 10.6 FGFR2 FGFR1
36 wolffian duct adenocarcinoma 10.6 KRT7 FGFR2
37 papillary tumor of the pineal region 10.6 VIM SYP
38 thymus sarcomatoid carcinoma 10.6 SYP AFP
39 synovium neoplasm 10.6 KRT8 KRT7
40 intrahepatic bile duct adenoma 10.6 KRT7 AFP
41 intrahepatic gall duct cancer 10.6 KRT8 KRT7
42 gastric neuroendocrine neoplasm 10.6 SYP GAST
43 benign metastasizing leiomyoma 10.6 VIM KRT7
44 laryngeal small cell carcinoma 10.6 SYP KRT7
45 rete testis neoplasm 10.6 KRT7 AFP
46 rete testis adenocarcinoma 10.6 KRT7 AFP
47 hidrocystoma 10.6 KRT8 KRT7
48 testicular spermatocytic seminoma 10.6 NR0B2 FGFR2
49 renal pelvis adenocarcinoma 10.6 KRT7 AFP
50 papillary squamous carcinoma 10.6 SYP KRT7

Graphical network of the top 20 diseases related to Fibrolamellar Carcinoma:



Diseases related to Fibrolamellar Carcinoma
Sources

Symptoms & Phenotypes for Fibrolamellar Carcinoma

About this section

UMLS symptoms related to Fibrolamellar Carcinoma:


fever, abdominal pain, icterus, malaise

GenomeRNAi Phenotypes related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.47 AFP
2 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.47 AFP
3 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.47 KRT8
4 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.47 KRT7 KRT8
5 Increased shRNA abundance (Z-score > 2) GR00366-A-180 9.47 KRT8
6 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.47 AFP KRT7 KRT8
7 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.47 AFP
8 Increased shRNA abundance (Z-score > 2) GR00366-A-6 9.47 KRT8
9 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.47 AFP
10 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.47 KRT7 KRT8

MGI Mouse Phenotypes related to Fibrolamellar Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.8 AFP CCKBR FGFR1 FGFR2 GAST ITGA1
2 digestive/alimentary MP:0005381 9.76 CCKBR FGFR1 FGFR2 GAST ITGAV ITGB4
3 renal/urinary system MP:0005367 9.23 CCKBR FGFR1 FGFR2 ITGA1 ITGAV ITGB4
Sources

Drugs & Therapeutics for Fibrolamellar Carcinoma

About this section

Drugs for Fibrolamellar Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 24)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vancomycin Approved Phase 2 1404-90-6 441141 14969
2
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
3
Fulvestrant Approved, Investigational Phase 2 129453-61-8 104741 17756771
4
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
5
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
6
Leuprolide Approved, Investigational Phase 2 53714-56-0 3911 657181
7
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
8
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
9
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
10
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
11 Antineoplastic Agents, Immunological Phase 2
12 Mitogens Phase 2
13 Antimitotic Agents Phase 2
14 Albumin-Bound Paclitaxel Phase 2
15 Cola Phase 2
16 Fertility Agents Phase 2
17 Estrogens Phase 2
18 Aromatase Inhibitors Phase 2
19 Antifungal Agents Phase 2
20 Steroid Synthesis Inhibitors Phase 2
21 Estrogen Receptor Antagonists Phase 2
22 Estrogen Antagonists Phase 2
23 Protein Kinase Inhibitors Phase 2
24 Angiogenesis Inhibitors Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Phase 2, Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma (FLC) Completed NCT02234986 Phase 2 ENMD-2076
2 Phase II Study of Oral Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Recruiting NCT04025567 Phase 2 vancomycin
3 An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification. Recruiting NCT01953926 Phase 2 Neratinib;Paclitaxel;Fulvestrant;Trastuzumab
4 A Randomized Three Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) Active, not recruiting NCT01642186 Phase 2 everolimus;letrozole plus leuprolide;combination of everolimus, letrozole and leuprolide
5 A Multicenter National Phase II Open Study Coupled With Translational Assessment of Biomarkers Predictive of Response to Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Hepatocellular Carcinoma. Terminated NCT01215565 Phase 2 Sutent
6 Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Fibrolamellar or Non-fibrolamellar Hepatocellular Carcinoma (HCC) Including Fibrolamellar HCC Withdrawn NCT02702960 Phase 2 Cyclophosphamide;Mesna;Filgrastim;Tacrolimus;mycophenolate mofetil;Prednisone;Antithymocyte globulin;fludarabine
7 A Natural History Study of Children and Adults With Fibrolamellar Hepatocellular Carcinoma Recruiting NCT03748927
8 Molecular Analysis of Liver Cancer Withdrawn NCT00899002

Search NIH Clinical Center for Fibrolamellar Carcinoma

Cochrane evidence based reviews: fibrolamellar hepatocellular carcinoma

Sources

Genetic Tests for Fibrolamellar Carcinoma

About this section
Sources

Anatomical Context for Fibrolamellar Carcinoma

About this section

MalaCards organs/tissues related to Fibrolamellar Carcinoma:

40
Liver, Lung, Ovary, Bone, Lymph Node, Bone Marrow, Testis
Sources

Publications for Fibrolamellar Carcinoma

About this section

Articles related to Fibrolamellar Carcinoma:

(show top 50) (show all 454)
# Title Authors PMID Year
1
Cytoreductive Surgery and HIPEC for Recurrent Fibrolamellar Hepatocellular Carcinoma with Peritoneal Carcinomatosis. 61
30989576 2020
2
Predictors of Outcome in Patients With Fibrolamellar Carcinoma: Analysis of the National Cancer Database. 61
32014928 2020
3
DNAJB1-PRKACA-positive metastatic fibrolamellar carcinoma with unknown primary in a pediatric patient. 61
31736218 2020
4
Single-Cell RNA Sequencing Identifies Yes-Associated Protein 1-Dependent Hepatic Mesothelial Progenitors in Fibrolamellar Carcinoma. 61
31669305 2020
5
Acute Onset Hyperammonemic Encephalopathy Related to Fibrolamellar Carcinoma: Another One Bites the Dust. 61
32014302 2020
6
Elevated Serum α-Fetoprotein is Associated with Abbreviated Survival for Patients with Fibrolamellar Hepatocellular Carcinoma Who Undergo a Curative Resection. 61
31925595 2020
7
Clavicle tumor as an initial manifestation of fibrolamellar hepatocellular carcinoma. 61
31677896 2020
8
Hyperammonemic encephalopathy: An unusual presentation of fibrolamellar hepatocellular carcinoma. 61
31422648 2020
9
Fibrolamellar hepatocellular carcinoma with paraneoplastic neuropsychiatric manifestations. 61
31965677 2020
10
BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA. 61
31862487 2019
11
Fibrolamellar hepatocellular carcinoma-related hyperammonemic encephalopathy: up to now and next steps. 61
31679315 2019
12
DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma. 61
31676785 2019
13
MDM4 expression in fibrolamellar hepatocellular carcinoma. 61
31322272 2019
14
Emerging Roles of GLI-Similar Krüppel-like Zinc Finger Transcription Factors in Leukemia and Other Cancers. 61
31474360 2019
15
Inhibition of the chimeric DnaJ-PKAc enzyme by endogenous inhibitor proteins. 61
30938854 2019
16
Hepatocellular Carcinoma of Fibrolamellar Type in an Adolescent: Case Report and Literature Review. 61
31602376 2019
17
Neurotensin as a source of cyclic AMP and co-mitogen in fibrolamellar hepatocellular carcinoma. 61
31489118 2019
18
A prognostic nomogram for patients with resected fibrolamellar hepatocellular carcinoma. 61
31489303 2019
19
Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma. 61
31183207 2019
20
Hyperammonemic encephalopathy in a patient with fibrolamellar hepatocellular carcinoma: case report and literature review. 61
31183212 2019
21
Spontaneous Rupture of Fibrolamellar Variant Hepatocellular Carcinoma. 61
31236158 2019
22
An acquired scaffolding function of the DNAJ-PKAc fusion contributes to oncogenic signaling in fibrolamellar carcinoma. 61
31063128 2019
23
Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma. 61
30902819 2019
24
Structures of the PKA RIα Holoenzyme with the FLHCC Driver J-PKAcα or Wild-Type PKAcα. 61
30905674 2019
25
Progression after Immunotherapy for Fibrolamellar Carcinoma. 61
31312648 2019
26
Update on the pathology of liver neoplasms. 61
30597357 2019
27
[Hepatocellular carcinomas and their mimics]. 61
30706100 2019
28
MicroRNA-375 Suppresses the Growth and Invasion of Fibrolamellar Carcinoma. 61
30763770 2019
29
Road map for fibrolamellar carcinoma: progress and goals of a diversified approach. 61
30951568 2019
30
Hardened Liver Due to Fibrolamellar Hepatocellular Carcinoma. 61
29505903 2019
31
State-of-the-art MR Imaging of Uncommon Hepatocellular Tumours: Fibrolamellar Hepatocellular Carcinoma and Combined Hepatocellularcholangiocarcinoma. 61
31989878 2019
32
Acquired ornithine transcarbamylase deficiency in pediatric and adolescent patients with fibrolamellar hepatocellular carcinoma. 61
30094907 2018
33
Fibrolamellar Hepatocellular Carcinoma with Multiple Lung Metastases Treated with Multidisciplinary Therapy. 61
30101933 2018
34
Hepatic Sclerosing Hemangioma Simulating Gallbladder Carcinoma: A Rare Case. 61
30564006 2018
35
Fibrolamellar hepatocellular carcinoma: multiphasic CT features of the primary tumor on pre-therapy CT and pattern of distant metastases. 61
29948061 2018
36
Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1-PRKACA fusion. 61
29222914 2018
37
Management of fibrolamellar hepatocellular carcinoma. 61
30395718 2018
38
Fibrolamellar Carcinoma: A Concise Review. 61
30141990 2018
39
Liver clear cell foci and viral infection are associated with non-cirrhotic, non-fibrolamellar hepatocellular carcinoma in young patients from South America. 61
30061721 2018
40
Favorable response to mammalian target of rapamycin inhibition in a young patient with unresectable fibrolamellar carcinoma of the liver. 61
29473972 2018
41
Fibrolamellar Carcinoma: What Is New and Why It Matters. 61
29751881 2018
42
Update on Ancillary Testing in the Evaluation of High-Grade Liver Tumors. 61
29751880 2018
43
Fibrolamellar Hepatocellular Carcinoma: Treatment with Yttrium-90 and Subsequent Surgical Resection. 61
29468286 2018
44
Utility of Cytokeratin7 Immunocytochemistry in the Cytopathological Diagnosis of Fibrolamellar Hepatocellular Carcinoma. 61
29643652 2018
45
Living-Donor Liver Transplant for Fibrolamellar Hepatocellular Carcinoma With Hilar Lymph Node Metastasis: A Case Report. 61
29633928 2018
46
Intracranial metastasis in fibrolamellar hepatocellular carcinoma. 61
29286561 2018
47
Imaging features of fibrolamellar hepatocellular carcinoma in gadoxetic acid-enhanced MRI. 61
29490696 2018
48
Fibrolamellar Carcinoma: Recent Advances and Unresolved Questions on the Molecular Mechanisms. 61
29471565 2018
49
Curative lung metastectomy and complete pathological response after neo-adjuvant GEMOX chemotherapy for relapse fibrolamellar hepatocellular carcinoma. 61
29531203 2018
50
Non coding RNA analysis in fibrolamellar hepatocellular carcinoma. 61
29535801 2018
Sources

Variations for Fibrolamellar Carcinoma

About this section

Cosmic variations for Fibrolamellar Carcinoma:

9 (show top 50) (show all 15431)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM97724722 ZXDB liver,NS,carcinoma,hepatocellular carcinoma c.1308C>A p.D436E 23:57593356-57593356 6
2 COSM94436083 ZSWIM1 liver,NS,carcinoma,hepatocellular carcinoma c.1399A>C p.S467R 20:45883991-45883991 6
3 COSM94063771 ZSCAN20 liver,NS,carcinoma,hepatocellular carcinoma c.2314G>T p.G772W 1:33494658-33494658 6
4 COSM88264637 ZRSR2 liver,NS,carcinoma,hepatocellular carcinoma c.304G>T p.E102* 23:15803788-15803788 6
5 COSM131494492 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.1159A>G p.M387V 22:29049340-29049340 6
6 COSM102131817 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860= 20:49257501-49257501 6
7 COSM113317148 ZNF853 liver,NS,carcinoma,hepatocellular carcinoma c.1610G>T p.G537V 7:6622601-6622601 6
8 COSM128686611 ZNF829 liver,NS,carcinoma,hepatocellular carcinoma c.1072T>A p.F358I 19:36891962-36891962 6
9 COSM123949383 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.1741C>T p.L581= 4:145885684-145885684 6
10 COSM86004822 ZNF653 liver,NS,carcinoma,hepatocellular carcinoma c.1553A>C p.H518P 19:11485673-11485673 6
11 COSM139729931 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 6
12 COSM91868668 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.3900G>T p.K1300N 19:30557161-30557161 6
13 COSM91880764 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.2171-78T>G p.? 19:30534769-30534769 6
14 COSM94799980 ZNF521 liver,NS,carcinoma,hepatocellular carcinoma c.3658+205G>A p.? 18:25194955-25194955 6
15 COSM90582798 ZNF518B liver,NS,carcinoma,hepatocellular carcinoma c.1624G>T p.E542* 4:10444705-10444705 6
16 COSM87577038 ZNF462 liver,NS,carcinoma,hepatocellular carcinoma c.6715G>T p.V2239L 9:106974156-106974156 6
17 COSM151538615 ZNF385B liver,NS,carcinoma,hepatocellular carcinoma c.253+23785G>T p.? 2:179745718-179745718 6
18 COSM111609487 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1444C>G p.L482V 16:89734008-89734008 6
19 COSM92353291 ZNF26 liver,NS,carcinoma,hepatocellular carcinoma c.1010C>T p.T337I 12:133010889-133010889 6
20 COSM95253159 ZNF217 liver,NS,carcinoma,hepatocellular carcinoma c.*194A>T p.? 20:53569094-53569094 6
21 COSM94505616 ZMYND12 liver,NS,carcinoma,hepatocellular carcinoma c.425-1G>T p.? 1:42440026-42440026 6
22 COSM89943752 ZMYM4 liver,NS,carcinoma,hepatocellular carcinoma c.86-8201G>T p.? 1:35350724-35350724 6
23 COSM101398456 ZIC2 liver,NS,carcinoma,hepatocellular carcinoma c.-18C>T p.? 13:99982047-99982047 6
24 COSM92703312 ZGPAT liver,NS,carcinoma,hepatocellular carcinoma c.*197C>A p.? 20:63736116-63736116 6
25 COSM92032561 ZFYVE26 liver,NS,carcinoma,hepatocellular carcinoma c.663C>A p.A221= 14:67807621-67807621 6
26 COSM84360265 ZFR liver,NS,carcinoma,hepatocellular carcinoma c.1979+14C>A p.? 5:32395145-32395145 6
27 COSM84362097 ZFR liver,NS,carcinoma,hepatocellular carcinoma c.2882C>T p.P961L 5:32364229-32364229 6
28 COSM85178149 ZFP36L2 liver,NS,carcinoma,hepatocellular carcinoma c.910T>G p.S304A 2:43224894-43224894 6
29 COSM87884183 ZFP28 liver,NS,carcinoma,hepatocellular carcinoma c.1865G>A p.C622Y 19:56554650-56554650 6
30 COSM127392053 ZFHX4 liver,NS,carcinoma,hepatocellular carcinoma c.10601C>G p.S3534C 8:76864315-76864315 6
31 COSM149268658 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.9997C>T p.Q3333* 16:72788279-72788279 6
32 COSM149328017 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.10852C>A p.P3618T 16:72787424-72787424 6
33 COSM149281099 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.8342A>G p.Q2781R 16:72794340-72794340 6
34 COSM144309108 ZEB2 liver,NS,carcinoma,hepatocellular carcinoma c.1141A>G p.M381V 2:144400046-144400046 6
35 COSM87420403 ZCCHC14 liver,NS,carcinoma,hepatocellular carcinoma c.71A>T p.Q24L 16:87491757-87491757 6
36 COSM98996636 ZC3H7A liver,NS,carcinoma,hepatocellular carcinoma c.2866A>G p.N956D 16:11751367-11751367 6
37 COSM92255466 ZC3H15 liver,NS,carcinoma,hepatocellular carcinoma c.*55T>G p.? 2:186508788-186508788 6
38 COSM85044193 ZC3H14 liver,NS,carcinoma,hepatocellular carcinoma c.*10873G>A p.? 14:88622624-88622624 6
39 COSM106743522 ZBTB7B liver,NS,carcinoma,hepatocellular carcinoma c.*635G>C p.? 1:155017320-155017320 6
40 COSM93795261 ZBTB41 liver,NS,carcinoma,hepatocellular carcinoma c.1700G>A p.R567K 1:197178489-197178489 6
41 COSM103188148 ZBTB40 liver,NS,carcinoma,hepatocellular carcinoma c.3339C>A p.F1113L 1:22524258-22524258 6
42 COSM91488114 ZBTB4 liver,NS,carcinoma,hepatocellular carcinoma c.454G>T p.G152C 17:7466348-7466348 6
43 COSM95291738 ZBTB37 liver,NS,carcinoma,hepatocellular carcinoma c.620G>C p.S207T 1:173870845-173870845 6
44 COSM107993551 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2383A>G p.I795V 8:80519295-80519295 6
45 COSM107993152 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2208A>G p.T736= 8:80518852-80518852 6
46 COSM86073785 ZBED4 liver,NS,carcinoma,hepatocellular carcinoma c.2225A>C p.E742A 22:49885887-49885887 6
47 COSM142300159 YTHDF3 liver,NS,carcinoma,hepatocellular carcinoma c.1580A>G p.N527S 8:63187582-63187582 6
48 COSM90849676 YOD1 liver,NS,carcinoma,hepatocellular carcinoma c.*157T>C p.? 1:207048863-207048863 6
49 COSM90620829 YME1L1 liver,NS,carcinoma,hepatocellular carcinoma c.2006A>G p.H669R 10:27116230-27116230 6
50 COSM86902201 YEATS2 liver,NS,carcinoma,hepatocellular carcinoma c.501C>T p.N167= 3:183722100-183722100 6
Sources

Expression for Fibrolamellar Carcinoma

About this section
Search GEO for disease gene expression data for Fibrolamellar Carcinoma.
Sources

Pathways for Fibrolamellar Carcinoma

About this section

Pathways related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Actin Nucleation by ARP-WASP Complex 63
Show member pathways
 12.78 ITGB4 ITGAV ITGA1 FGFR2 FGFR1
2
PI3K-Akt signaling pathway 36
Show member pathways
 12.77 PRKACA ITGB4 ITGAV ITGA1 FGFR2 FGFR1
3
NFAT and Cardiac Hypertrophy 63
Show member pathways
 12.54 PRKACA ITGB4 ITGAV ITGA1 FGFR2 FGFR1
4
Regulation of actin cytoskeleton 36 1
12.39 ITGB4 ITGAV ITGA1 FGFR2 FGFR1
5
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.2 ITGB4 ITGAV ITGA1 FGFR2 FGFR1
6
Dilated cardiomyopathy (DCM) 36
Show member pathways
 12.07 PRKACA ITGB4 ITGAV ITGA1
7
VEGF Signaling Pathway 66 60
Show member pathways
 12.03 ITGAV ITGA1 FGFR2 FGFR1
8
MAPK Signaling: Mitogen Stimulation Pathway 64
Show member pathways
 11.74 ITGB4 ITGAV ITGA1 FGFR2 FGFR1
9
Angiogenesis (CST) 4
11.68 ITGAV FGFR2 FGFR1
10
Phagocytosis of Microbes 63
11.64 ITGB4 ITGAV ITGA1
11
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.6 VIM SYP FGFR1
12
Cell adhesion_Endothelial cell contacts by non-junctional mechanisms 22
11.15 ITGB4 ITGAV ITGA1
13
Primary Focal Segmental Glomerulosclerosis FSGS 1
11.13 VIM KRT8 ITGB4 ITGAV
14
G-protein signaling_RhoA regulation pathway 22
10.79 PRKACA ITGB4 ITGAV ITGA1 FGFR2 FGFR1
15
G-protein signaling_Rap2B regulation pathway 22
10.64 VIM ITGB4 ITGAV ITGA1 FGFR2 FGFR1
16
Secretion of Hydrochloric Acid in Parietal Cells 1
10.1 GAST CCKBR
Sources

GO Terms for Fibrolamellar Carcinoma

About this section

Cellular components related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integrin complex GO:0008305 8.8 ITGB4 ITGAV ITGA1

Biological processes related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 integrin-mediated signaling pathway GO:0007229 9.67 ITGB4 ITGAV ITGA1
2 cell-matrix adhesion GO:0007160 9.65 ITGB4 ITGAV ITGA1
3 regulation of osteoblast differentiation GO:0045667 9.51 PRKACA FGFR2
4 mesodermal cell differentiation GO:0048333 9.46 ITGB4 FGFR2
5 branching involved in salivary gland morphogenesis GO:0060445 9.43 FGFR2 FGFR1
6 mesenchymal cell differentiation GO:0048762 9.4 FGFR2 FGFR1
7 positive regulation of phospholipase activity GO:0010518 9.37 FGFR2 FGFR1
8 digestive tract development GO:0048565 9.33 ITGB4 FGFR2 CCKBR
9 lung-associated mesenchyme development GO:0060484 9.32 FGFR2 FGFR1
10 orbitofrontal cortex development GO:0021769 9.26 FGFR2 FGFR1
11 ventricular zone neuroblast division GO:0021847 8.96 FGFR2 FGFR1
12 fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development GO:0035607 8.62 FGFR2 FGFR1

Molecular functions related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 insulin-like growth factor I binding GO:0031994 9.26 ITGB4 ITGAV
2 neuregulin binding GO:0038132 9.16 ITGB4 ITGAV
3 fibroblast growth factor-activated receptor activity GO:0005007 8.96 FGFR2 FGFR1
4 fibroblast growth factor binding GO:0017134 8.8 ITGAV FGFR2 FGFR1
Sources

Sources for Fibrolamellar Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....